Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 3, 2014, Pages 207-215

  Alhan, Canan ^a   Westers, Theresia M ^a   Van Der Helm, Lieke H ^b   Eeltink, Corien ^a   Huls, Gerwin ^c   Witte, Birgit I ^a   Buchi, Francesca ^d   Santini, Valeria ^d   Ossenkoppele, Gert J ^a   Van De Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

azacitidine; flow cytometry; myelodysplastic syndromes; response prediction

Indexed keywords

AZACITIDINE; CD34 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE; PHARMACOLOGICAL BIOMARKER;

ABERRANT MYELOID PROGENITOR; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMATOPOIETIC CELL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; BONE MARROW CELL; CLASSIFICATION; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; METHODOLOGY; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOMARKERS, PHARMACOLOGICAL; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELLS; PROGNOSIS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84898544441     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21160     Document Type: Article

References (30)

1. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D,. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J,. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
3. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paguette R, Maciejewski JP,. Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 2008; 100: 1542-1551.
4. Cutler C,. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program 2010; 2010: 325-329.
5. Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Celghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P,. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403-411.
6. van der Helm L, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G,. Platelet doubling after the first azacitidine cycle is a promising predictor for response in MDS, CMML and AML patients in the Dutch azacitidine compassionate patient named program. Br J Haematol 2011; 155: 599-606.
7. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ,. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndromes correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
8. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ,. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008; 112: 2861-2866.
9. van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ,. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 1067-1077.
10. Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ, van de Loosdrecht AA,. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010; 115: 1779-1784.
11. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC; 2008.
12. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D,. New comprehensive cytogenetics scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820-829.
13. Mitelman F, editor. ISCN: An International System for Human Cytogenetic Nomenclature 1995. Basel, Switzerland: Karger; 1995.
14. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter B, Sperr WR, Stauder R, Wells DA,. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
15. Cheson BD, Greenberg PL, Bennett JM, Löwenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H,. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
16. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL,;, World Health Organization (WHO,) international working group,. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
17. van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM,. Standardization of flow cytometry in myelodysplastic syndromes: Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94: 1124-1134.
18. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA,. Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet working group. Leukemia 2012; 27: 1730-1741.
19. Sandes AF, Kerbauy DM, Matarraz S, Chauffaille Mde L, Lõpez A, Orfao A, Yamamoto M,. Combined flow cytometric assessment of CD45, HLA-DR, CD34 and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. Cytometry Clin Cytom 2013; 84B: 157-166.
20. Terwijn M, Feller N, van Rhenen A, Kelder A, Westra G, Zweegman S, Ossenkoppele G, Schuurhuis GJ,. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer 2009; 45: 1692-1699.
21. van der Pol MA, Pater JM, Feller N, Westra AH, van Stijn A, Ossenkoppele GJ, Boxterman HJ, Schuurhuis GJ,. Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 2001; 15: 1554-1563.
22. Chu SC, Wang TF, Li CC, Kao RH, Li DK, Su YC, Wells DA, Loken MR,. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 2011; 35: 868-873.
23. List AF, Fenaux P, Mufti GJ, Hellström-Lindberg E, Gore S, Bennett JM, Silverman LR, Backstrom J, Allen AR, Beach CL,. Effect of azacitidine (AZ) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol 2008; 26 (suppl):Abstract 7006.
24. Fenaux P, Ades L,. Review of azacitidine trials in intermediate-2 and high-risk myelodysplastic syndromes. Leuk Res 2009; 33 (suppl 2): S7-S11.
25. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Schanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR,;, International Vidaza High-Risk MDS, Survival Study Group,. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomized open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
26. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA,. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921 and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903.
27. Silverman LR,. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: The value of azacitidine maintenance therapy, effects on transfusion and combination with other agents. Leuk Res 2009; 33 (suppl 2): S18-S21.
28. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, Iwakiri R, Hayashi T, Sakamaki H, Murai Y, Tohyama K, Tomoyasu S, Nonaka Y, Mori M, Dan K, Yoshida Y,. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndromes. Blood 2002; 100: 3887-3896.
29. Matarraz S, Lõpez A, Barrena S, Fernandez C, Jensen E, Flores J, Bárcena P, Rasillo A, Sayagues JM, Sánchez ML, Hernandez-Campo P, Hernandez Rivas JM, Salvador C, Fernandez-Mosteirín N, Giralt M, Perdiguer L, Orfao A,. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008; 22: 1175-1183.
30. Matarraz S, Lõpez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, Rasillo A, Sayagues JM, Sánchez ML, Bárcena P, Hernandez Rivas JM, Salvador C, Fernandez-Mosteirín N, Giralt M, Perdiguer L, Laranjeira P, Paiva A, Orfao A,. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients. Cytometry B Clin Cytom 2010; 78B: 154-168.